Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin
Li Y, Ettah U, Jacques S, Gaikwad H, Monte A, Dylla L, Guntupalli S, Moghimi S, Simberg D. Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin. Molecular Pharmaceutics 2024, 21: 3053-3060. PMID: 38743264, DOI: 10.1021/acs.molpharmaceut.4c00278.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayLiposomal doxorubicinHealthy donorsPatients treated with pegylated liposomal doxorubicinEnzyme-linked immunosorbent assay signalCancer patientsAnti-PEG IgGPegylated liposomal doxorubicinImmunosorbent assayOptimized ELISAEnzyme-linked immunosorbent assay protocolsAnti-PEG antibodiesChemotherapy cyclesBetween-assay variabilityPEGylated liposomesCutoff valueAccelerated clearanceTreatment cyclesDrug delivery systemsAntibody titersComplement activationInfused drugAnti-PEGOptimized assayPatients